Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Using GLP-1 RAs alongside other glucose-lowering or cardiovascular medications can significantly enhance therapeutic outcomes, reduce side effects, and better address the diverse needs of different patients
Phase 2 trial data (NEJM, 2023) reported a mean body weight reduction of approximately 24% over 48 weeks at the highest dose, though larger Phase 3 trials are needed to confirm these findings
Clinical weight loss data that drove the conversation Numbers matter
It is with deep sadness that we share the news of the passing of Joel Habener, MD, an extraordinary physician-scientist, mentor, and beloved member of our Mass General Brigham community whose discoveries transformed the field of endocrinology and the care of millions of patients worldwide
Nausea, vomiting, and gastrointestinal issues are well-documented
